Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evotec AG ( (EVO) ) has shared an announcement.
On 10 March 2026, Evotec SE unveiled “Horizon,” the next phase of its strategic transformation, introducing a new operating model built around operations, science and commercial execution to drive above-market growth and agility. The plan includes consolidating its global footprint to 10 sites, creating Centers of Excellence, and adjusting its workforce by up to 800 positions, with implementation underway and substantial completion targeted by end-2027.
Horizon is expected to deliver about €75 million in annual run-rate savings by 2027, supported by roughly €100 million in restructuring cash charges over 2026–2028 and additional non-cash impairments. Evotec also outlined a 2026–2030 financial framework, projecting group revenues above €1 billion with 8–12% CAGR and an adjusted EBITDA margin of 20% by 2028, while confirming that preliminary 2025 results will land at the upper end of guidance, underlining a shift toward higher-margin, technology-led revenues and improved long-term profitability.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. The company is struggling with profitability and cash flow issues, reflected in a negative P/E ratio and lack of dividend yield. Technical analysis shows a bearish trend, further weighing on the score. Despite some positive developments from the earnings call, such as growth in the Biologics segment and strategic partnerships, these are not enough to offset the significant financial challenges.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a German drug discovery and preclinical development company that partners with pharma and biotech clients to provide integrated R&D services and technology platforms. The group operates through its Discovery & Preclinical Development segment and Just – Evotec Biologics unit, focusing on high-value, technology-driven programs in biologics and small molecules.
Average Trading Volume: 180,730
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.09B
See more insights into EVO stock on TipRanks’ Stock Analysis page.